Payments by drug and device makers to doctors remain widespread, but also vary considerably
The financial ties between drug and device makers and some physicians remains pervasive, according to a new analysis.
The financial ties between drug and device makers and some physicians remains pervasive, according to a new analysis.
Zach Klaassen discusses the ARAMON trial with Andrew Laccetti, which focuses on the impact of enzalutamide and darolutamide on testosterone levels in patients with high-risk…
APCCC 2024, Advanced Prostate Cancer, How to Select Patients for Adjuvant Therapy After Radical Prostatectomy, pT3bN, RADICALS-RT trial, Adjuvant external beam radiotherapy, androgen deprivation therapy…
Takeda Pharmaceuticals has left BIO, the fourth departure of a major member since December, the company confirmed.
This e-book provides information about the advantages and disadvantages of different activity tracking solutions in research use. The guide is not a systematic review but…
Sam Chang and Roger Li delve into a study examining genetic profiles in non-muscle invasive bladder cancer and adjacent benign bladder tissue. Conducted on a…
Genetic evidence of H5N1 bird flu virus has been found in grocery store milk, according to the FDA. In this video, STAT explains what is…
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies:…
Biogen on Wednesday reported first-quarter earnings that beat Wall Street expectations largely on reduced expenses.
The authors of a new study argue the heralded arrival of biosimilars failed to fully deliver on their promise.
As the Covid-19 experience showed, trying to address IP during a pandemic doesn’t work, and voluntary sharing of IP during a pandemic doesn’t work.